Sumitovant, Sumitomo Pharma approaches Myovant Sciences (MYOV) with $2.5 billion buyout offer
Sumitovant Biopharma Ltd., a wholly-owned subsidiary of Sumitomo Pharma Co, announced it has submitted a non-binding proposal to the Audit Committee of the Board of
Read More